OUTFRONT Media Inc. Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? OUTFRONT Media Inc. Common Stock trades at $29.55 (market cap $5.33B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 4.7× OUTFRONT Media Inc. Common Stock's market cap, and OUTFRONT Media Inc. Common Stock pays a 4.06% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold OUTFRONT Media Inc. Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| OUT | ROIV | |
|---|---|---|
Market Cap | $5.33B | $24.99B |
Volume | 1,197,618 | 4,711,562 |
Sector | Real Estate | Health |
52-Week High | $33.90 | $41.81 |
52-Week Low | $17.08 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.43B | $21.25B |
Dividend Yield | 4.06% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
OUTFRONT Media Inc. is a US out-of-home media REIT that provides advertising space on billboard and transit displays across major markets in US and Canada.
Read more on OUT →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →